Notably, CXCL2-evoked colon cancer cell proliferation and migration were dose-dependently attenuated by co-incubation with the CXCR2 antagonist SB225002 (Fig. 2C and D, respectively). This evidence concerns the gene CXCL2 and colonic neoplasm.